Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />
JAPAN<br />
CIBA VI SION<br />
Full Name: CIBA Vi sion K.K.<br />
Street Ad dress: Tennoz Cen tral Tower 13 F.,<br />
2-2-24 Higashi-shinagawa, Shinagawa-ku, To kyo<br />
140-0002<br />
Tel: +81 3 5461 1301<br />
Fax: +81 3 5461 1396<br />
Home Page: www.cibavision.jp<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
NOVARTIS<br />
Full Name: Novartis Pharma KK<br />
Street Ad dress: Nishi-Azabu Mitsui Bldg, 17-30<br />
Nishi-Azabu 4-chome, Minato-ku, To kyo<br />
106-8618<br />
Tel: +81 3 3797 8000<br />
Fax: +81 3 3797 4496<br />
Home Page: www.novartis.co.jp<br />
De scrip tion: Re searcher, de vel oper, man u fac -<br />
turer, for mu la tor, packager/as sem bler, im porter,<br />
dis trib u tor, pro moter, sales/detailer. Man u fac -<br />
tures, dis trib utes, pro motes, sells/de tails for other<br />
com pa nies. Prod uct ranges in clude: phar ma ceu ti -<br />
cal prod ucts (branded, pre scrip tion), hos pi tal<br />
pharmaceuticals, di ag nos tic prod ucts, oph thal mic<br />
prod ucts. 3,500 pharmaceutical employees in<br />
2007.<br />
Rep re sen ta tives/De tail ers (Pharm, Num -<br />
ber): 1,501-2,000 (2007)<br />
Con tacts (Pharm): Chair man: H. Mitani; Mar ket<br />
Re search: M. Saito; Gen eral Con tact: M. Saito<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
Phar ma ceu ti cal Sales: US$ 2,500-2,600 mil -<br />
lion<br />
Prod ucts (% of Sales by Lead ing 5): 70-75%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 65-70%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
85-90%<br />
Prin ci pal Prod ucts:<br />
DIOVAN (an gio ten sin-II an tag o nist plain)<br />
GLIVEC (antineoplastic other)<br />
VOLTAREN (antirheumatic non-steroidal;<br />
antirheumatic top i cal)<br />
NEORAL (immunosuppressive agent)<br />
LAMISIL NOVARTIS (antifungal sys temic;<br />
dermatological antifungal)<br />
Ther a peu tic Range:<br />
renin-an gio ten sin sys tem agents 40%<br />
antineoplastics 13%<br />
immunosuppressive agents 7%<br />
antifungals sys temic 4%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions 4%<br />
Lead ing Dose Forms:<br />
coated tab lets 63%<br />
tab lets 9%<br />
cap sules 8%<br />
med i cal dress ings 5%<br />
in fu sions 4%<br />
JORDAN<br />
NOVARTIS<br />
Full Name: Novartis Pharma Ser vices AG<br />
Postal Ad dress: PO Box 851698, Amman,<br />
11185<br />
Street Ad dress: Um Outhina, Shat Al-Arab<br />
Street, op po site to Red Rose ho tel, Mousa Nakho<br />
Build ing, Amman, 11110<br />
Tel: +962 6 5544101<br />
Fax: +962 6 5544406<br />
Home Page: www.mea.novartis.com<br />
Con tacts (Pharm): Gen eral Con tact: Habib<br />
Ihsan<br />
Phar ma ceu ti cal Sales: US$ 4-5 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 50-55%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 75-80%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
95-100%<br />
Prin ci pal Prod ucts:<br />
CO DIOVAN (an gio ten sin-II an tag o nist com bi na -<br />
tion)<br />
LESCOL (cho les terol/triglyceride reg u lat ing prep -<br />
a ra tion)<br />
VOLTAREN (antirheumatic non-steroidal)<br />
DIOVAN (an gio ten sin-II an tag o nist plain)<br />
TEGRETOL (antiepileptic)<br />
Ther a peu tic Range:<br />
renin-an gio ten sin sys tem agents 30%<br />
ophthalmologicals 18%<br />
anti rheu ma tics sys temic 14%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions<br />
10%<br />
antiepileptics 7%<br />
Lead ing Dose Forms:<br />
coated tab lets 32%<br />
tab lets 28%<br />
liq uids 19%<br />
cap sules 12%<br />
am poules 4%<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 182
Change language